Amlodipine
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Amlodipine
- Pharmacist Assessment Report
- Amlodipine: dihydropyridine calcium channel blocker → brain stem infarction
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Amlodipine: dihydropyridine calcium channel blocker → brain stem infarction
One-Sentence Summary
Amlodipine is an oral dihydropyridine calcium channel blocker that is marketed in Australia. The TxGNN model predicts it may be useful for brain stem infarction, but the data compiled for this report contain no clinical trials and no publications that study this condition directly, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | brain stem infarction |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Amlodipine is a calcium channel blocker, a class that relaxes vascular smooth muscle by limiting calcium entry into the cells. Brain stem infarction is an ischaemic cerebrovascular event, so a drug acting on vascular tone and blood pressure could plausibly be relevant to it.
This is a general pharmacological argument, not evidence for this specific condition. No study in the compiled data tests amlodipine in brain stem infarction, and the model score has not been confirmed by any trial or publication. The brain stem is a small, anatomically distinct region, so findings from other cerebrovascular conditions cannot simply be assumed to apply.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Amlodipine is marketed in Australia. The local records show one valid single-ingredient licence, for an oral tablet (5 mg, as besilate). The approved indication is not recorded in the local data.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 recorded interactions. The 20 shown in the compiled data are all graded Moderate, including:
- corticosteroids (hydrocortisone, betamethasone, budesonide, dexamethasone)
- aprepitant
- acetylsalicylic acid
- bupropion
- clarithromycin
- clotrimazole
- SGLT2 inhibitors (canagliflozin, dapagliflozin)
- several calcium salts (acetate, carbonate, chloride, citrate, gluconate, lactate, phosphate and others)
Warning and contraindication text from the TGA-approved Product Information was not available in the compiled data. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no trial or publication studies amlodipine in brain stem infarction. The evidence level is therefore L5 (model prediction only), and there is nothing to support moving forward.
To proceed, the following is needed:
- Clinical or observational studies that directly address brain stem infarction, ideally with a specific focus on amlodipine
- Detailed mechanism of action data
- Review of the TGA-approved Product Information for warnings, contraindications and the registered indication
- A safety plan covering hypotension risk in acute ischaemic stroke and the moderate-level interactions noted above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.